Association between advanced paternal age and congenital heart defects: a systematic review and meta-analysis

F Joinau-Zoulovits1,2, N Bertille1, J F Cohen1,3

  • 1INSERM UMR 1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), Center for Epidemiology and Statistics, Sorbonne Paris Cité (CRESS), DHU Risks in Pregnancy, Paris Descartes University, F-75004 Paris, France.

Insights

Advanced paternal age is linked to a 16% increased risk of congenital heart defects (CHD). This association, while present, is modest and may not be sufficient for targeted screening.

Area of Science:

  • Reproductive Health
  • Pediatrics
  • Cardiovascular Science

Background:

  • Congenital heart defects (CHD) are the most common congenital malformations.
  • Existing research has identified several risk factors for CHD, but the link with advanced paternal age remains unclear.

Purpose of the Study:

  • To systematically evaluate the association between advanced paternal age (fathers ≥35 years) and the risk of congenital heart defects (CHD).

Main Methods:

  • A systematic literature search was conducted on MEDLINE and EMBASE (1960-2019).
  • Nine observational studies, encompassing over 9.9 million participants, were included in a random-effects meta-analysis.
  • Studies were selected based on their assessment of paternal age and CHD risk, with data extraction and bias assessment performed by two independent reviewers.

Main Results:

  • The meta-analysis of nine studies revealed a statistically significant association between advanced paternal age and an increased risk of CHD (summary OR 1.16, 95% CI 1.07-1.25).
  • This increased risk corresponds to an approximate 16% rise in the overall odds of CHD.
  • The findings were consistent across population-based studies and those with a low risk of bias.

Conclusions:

  • Advanced paternal age appears to be a contributing risk factor for congenital heart defects.
  • The modest magnitude of this association suggests its limited utility as a standalone criterion for targeted CHD screening.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
748
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
123
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
248
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
593
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.1K